Project Grant R44DA061908
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$326K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75225, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Federal Grant Program "Drug Use and Addiction Research Programs" (CFDA 93.279), will fund research to simulate the potential impacts of different methadone treatment policy scenarios in New York State. The $683,583 award, spanning 2 years from August 1, 2024 to July 31, 2026, will support the development of an agent-based computer simulation model to estimate the effects of policy changes such as...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop efficient statistical methods for data fusion to improve the power and external validity of clinical trials for treating opioid use disorder. The $564,326 award, with a performance period from August 2024 to May 2029, will fund the development of new parametric and semiparametric estimators for average treatment effects,...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $390,000.00 to the Regents of the University of Michigan to pilot an innovative digital Contingency Management (CM) intervention for individuals with co-occurring opioid and alcohol use disorders. The study aims to: 1) identify optimal settings and approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will assess the acceptability and feasibility of using pharmacogenomic (PGx) testing to guide opioid use disorder (OUD) treatment. The $195,728 award to Washington State University, effective January 1, 2025 through December 31, 2029, will: Identify barriers and facilitators impacting the acceptability and feasibility of a PGx testing protocol to inform OUD...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) provides $318,257 to Cari Health, Inc. to develop a therapeutic monitoring system (TMS) for remote medication compliance tracking of methadone treatment for opioid use disorder (OUD). The key products and services to be delivered include: 1) Integrating an electrochemical sensor, microneedle array, and data pipeline into a prototype wearable...
This federal Project Grant award of $1,264,863 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a study to evaluate the efficacy of combined guanfacine (GXR) and mindfulness-based recovery enhancement (MORE) as an adjunct to buprenorphine maintenance treatment for individuals with opioid use disorder (OUD). The study will first confirm the independent and combined efficacy of GXR and MORE in a sample of 80 OUD...
The National Institute on Drug Abuse (NIDA) awarded a $2,402,305 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Cari Health, Inc. (Doing Business As: Clinical Addiction Recovery Institute) to develop and commercialize a new point-of-care technology to enable individualized methadone dosing for opioid use disorder (OUD) treatment. The project aims to create a device that can quickly evaluate a patient's methadone metabolism rate using a small blood...
This federal Project Grant award of $177,170 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to analyze the implementation of medications for opioid use disorder (MOUD) treatment in Massachusetts jails. The study aims to qualitatively assess organizational factors related to MOUD implementation and post-release overdose risk, investigate the association between staff perspectives and organizational factors,...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify small-molecule compounds that can selectively modulate the G9A protein complex, which regulates the expression of DFosB in the brain during chronic opioid exposure. The work will involve a...
The federal Project Grant award of $314,225 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to explore the unique neurobehavioral effects of concurrent opioid and methamphetamine use disorders. The study aims to: 1) define the behavioral profile of dual opioid-methamphetamine use disorders in a rodent model, and 2) map neural activation patterns within the cortico-basal ganglia-thalamic circuit in response to...